Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Larimar Therapeutics, Inc. stock logo
LRMR
Larimar Therapeutics
$1.99
+8.7%
$2.10
$1.61
$11.20
$127.42M0.93771,438 shs1.10 million shs
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
$0.93
+28.0%
$0.92
$0.72
$2.60
$36.47M1.65165,368 shs1.34 million shs
Protara Therapeutics, Inc. stock logo
TARA
Protara Therapeutics
$3.15
-0.3%
$3.74
$1.60
$10.48
$121.53M1.73771,050 shs257,380 shs
Ventyx Biosciences, Inc. stock logo
VTYX
Ventyx Biosciences
$1.77
+0.6%
$1.24
$0.78
$5.66
$125.96M0.731.34 million shs1.18 million shs
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Larimar Therapeutics, Inc. stock logo
LRMR
Larimar Therapeutics
+8.74%+3.11%-15.32%-31.85%-73.04%
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
+28.04%+21.26%-3.64%-6.15%-60.39%
Protara Therapeutics, Inc. stock logo
TARA
Protara Therapeutics
-0.32%-3.08%-10.51%-7.08%+12.90%
Ventyx Biosciences, Inc. stock logo
VTYX
Ventyx Biosciences
+0.57%+15.69%+42.74%+22.07%-65.50%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Larimar Therapeutics, Inc. stock logo
LRMR
Larimar Therapeutics
1.875 of 5 stars
3.61.00.00.03.31.70.0
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
0.6452 of 5 stars
0.02.00.00.03.30.80.6
Protara Therapeutics, Inc. stock logo
TARA
Protara Therapeutics
3.5229 of 5 stars
4.63.00.00.04.00.80.6
Ventyx Biosciences, Inc. stock logo
VTYX
Ventyx Biosciences
3.1152 of 5 stars
3.43.00.00.04.22.50.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Larimar Therapeutics, Inc. stock logo
LRMR
Larimar Therapeutics
3.10
Buy$20.43926.56% Upside
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
0.00
N/AN/AN/A
Protara Therapeutics, Inc. stock logo
TARA
Protara Therapeutics
3.14
Buy$20.50550.79% Upside
Ventyx Biosciences, Inc. stock logo
VTYX
Ventyx Biosciences
2.75
Moderate Buy$10.00464.97% Upside

Current Analyst Ratings Breakdown

Latest SCYX, TARA, VTYX, and LRMR Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/22/2025
Protara Therapeutics, Inc. stock logo
TARA
Protara Therapeutics
Jones Trading
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy$21.00
4/28/2025
Protara Therapeutics, Inc. stock logo
TARA
Protara Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$23.00 ➝ $23.00
4/16/2025
Protara Therapeutics, Inc. stock logo
TARA
Protara Therapeutics
Scotiabank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageSector Outperform$12.00
3/25/2025
Larimar Therapeutics, Inc. stock logo
LRMR
Larimar Therapeutics
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
3/25/2025
Larimar Therapeutics, Inc. stock logo
LRMR
Larimar Therapeutics
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$26.00 ➝ $26.00
3/25/2025
Larimar Therapeutics, Inc. stock logo
LRMR
Larimar Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$15.00 ➝ $16.00
3/25/2025
Larimar Therapeutics, Inc. stock logo
LRMR
Larimar Therapeutics
Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$13.00 ➝ $10.00
3/14/2025
Protara Therapeutics, Inc. stock logo
TARA
Protara Therapeutics
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight
3/11/2025
Protara Therapeutics, Inc. stock logo
TARA
Protara Therapeutics
Lifesci Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$22.00
3/6/2025
Protara Therapeutics, Inc. stock logo
TARA
Protara Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$23.00 ➝ $23.00
(Data available from 5/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Larimar Therapeutics, Inc. stock logo
LRMR
Larimar Therapeutics
N/AN/AN/AN/A$1.86 per shareN/A
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
$2.63M13.87$1.61 per share0.58$1.96 per share0.48
Protara Therapeutics, Inc. stock logo
TARA
Protara Therapeutics
N/AN/AN/AN/A$6.01 per shareN/A
Ventyx Biosciences, Inc. stock logo
VTYX
Ventyx Biosciences
N/AN/AN/AN/A$4.13 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Larimar Therapeutics, Inc. stock logo
LRMR
Larimar Therapeutics
-$36.95M-$1.49N/AN/AN/AN/A-35.87%-32.37%8/6/2025 (Estimated)
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
$67.04M-$0.56N/A18.69N/A-425.41%-66.21%-38.84%8/6/2025 (Estimated)
Protara Therapeutics, Inc. stock logo
TARA
Protara Therapeutics
-$40.42M-$1.72N/AN/AN/AN/A-55.96%-49.06%8/5/2025 (Estimated)
Ventyx Biosciences, Inc. stock logo
VTYX
Ventyx Biosciences
-$192.96M-$1.75N/AN/AN/AN/A-54.94%-50.01%8/14/2025 (Estimated)

Latest SCYX, TARA, VTYX, and LRMR Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/15/2025Q1 2025
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
-$0.23-$0.17+$0.06-$0.11$0.14 million$0.26 million
5/8/2025Q1 2025
Protara Therapeutics, Inc. stock logo
TARA
Protara Therapeutics
-$0.47-$0.29+$0.18-$0.29N/AN/A
5/8/2025Q1 2025
Ventyx Biosciences, Inc. stock logo
VTYX
Ventyx Biosciences
-$0.48-$0.39+$0.09-$0.39N/AN/A
4/30/2025Q1 2025
Larimar Therapeutics, Inc. stock logo
LRMR
Larimar Therapeutics
-$0.42-$0.46-$0.04-$0.46N/AN/A
3/24/2025Q4 2024
Larimar Therapeutics, Inc. stock logo
LRMR
Larimar Therapeutics
-$0.29-$0.45-$0.16-$0.45N/AN/A
3/12/2025Q4 2024
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
-$0.22-$0.09+$0.13-$0.09N/A$0.98 million
3/12/2025Q4 2024
Protara Therapeutics, Inc. stock logo
TARA
Protara Therapeutics
-$0.57-$0.48+$0.09-$0.48N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Larimar Therapeutics, Inc. stock logo
LRMR
Larimar Therapeutics
N/AN/AN/AN/AN/A
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
N/AN/AN/AN/AN/A
Protara Therapeutics, Inc. stock logo
TARA
Protara Therapeutics
N/AN/AN/AN/AN/A
Ventyx Biosciences, Inc. stock logo
VTYX
Ventyx Biosciences
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Larimar Therapeutics, Inc. stock logo
LRMR
Larimar Therapeutics
N/A
13.10
13.10
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
N/A
3.13
3.13
Protara Therapeutics, Inc. stock logo
TARA
Protara Therapeutics
N/A
9.85
9.85
Ventyx Biosciences, Inc. stock logo
VTYX
Ventyx Biosciences
N/A
23.52
23.52

Institutional Ownership

CompanyInstitutional Ownership
Larimar Therapeutics, Inc. stock logo
LRMR
Larimar Therapeutics
91.92%
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
54.37%
Protara Therapeutics, Inc. stock logo
TARA
Protara Therapeutics
38.13%
Ventyx Biosciences, Inc. stock logo
VTYX
Ventyx Biosciences
97.88%

Insider Ownership

CompanyInsider Ownership
Larimar Therapeutics, Inc. stock logo
LRMR
Larimar Therapeutics
4.50%
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
4.86%
Protara Therapeutics, Inc. stock logo
TARA
Protara Therapeutics
8.40%
Ventyx Biosciences, Inc. stock logo
VTYX
Ventyx Biosciences
14.49%
CompanyEmployeesShares OutstandingFree FloatOptionable
Larimar Therapeutics, Inc. stock logo
LRMR
Larimar Therapeutics
3064.03 million61.57 millionOptionable
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
6039.02 million36.87 millionOptionable
Protara Therapeutics, Inc. stock logo
TARA
Protara Therapeutics
3038.58 million18.05 millionOptionable
Ventyx Biosciences, Inc. stock logo
VTYX
Ventyx Biosciences
3071.16 million57.86 millionOptionable

Recent News About These Companies

Ventyx Biosciences announces seven additional appointments to SAB
H.C. Wainwright Sticks to Their Hold Rating for Ventyx Biosciences (VTYX)
Ventyx Biosciences’ VTX958 shows efficacy in Crohn’s Disease

New MarketBeat Followers Over Time

Media Sentiment Over Time

Larimar Therapeutics stock logo

Larimar Therapeutics NASDAQ:LRMR

$1.99 +0.16 (+8.74%)
Closing price 05/28/2025 04:00 PM Eastern
Extended Trading
$2.03 +0.04 (+2.01%)
As of 05/28/2025 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease. Larimar Therapeutics, Inc. is based in Bala Cynwyd, Pennsylvania.

SCYNEXIS stock logo

SCYNEXIS NASDAQ:SCYX

$0.93 +0.20 (+28.04%)
Closing price 05/28/2025 04:00 PM Eastern
Extended Trading
$0.92 -0.02 (-2.11%)
As of 05/28/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

SCYNEXIS, Inc., a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. It offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp, an intravenous drug for the treatment of invasive candidiasis and/or candidemia, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC. It also develops SCY-247 to treat systemic fungal diseases. The company has licensing and collaboration agreements with GlaxoSmithKline Intellectual Property (No. 3) Limited, Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC for the development, manufacture, and commercialization of ibrexafungerp. SCYNEXIS, Inc. was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. The company was incorporated in 1999 and is headquartered in Jersey City, New Jersey.

Protara Therapeutics stock logo

Protara Therapeutics NASDAQ:TARA

$3.15 -0.01 (-0.32%)
Closing price 05/28/2025 04:00 PM Eastern
Extended Trading
$3.20 +0.05 (+1.59%)
As of 05/28/2025 07:22 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations. It is also developing intravenous choline chloride, an investigational phospholipid substrate replacement therapy that is in Phase II clinical trial for patients receiving parenteral nutrition. The company is headquartered in New York, New York.

Ventyx Biosciences stock logo

Ventyx Biosciences NASDAQ:VTYX

$1.77 +0.01 (+0.57%)
Closing price 05/28/2025 04:00 PM Eastern
Extended Trading
$1.85 +0.08 (+4.52%)
As of 05/28/2025 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease. It is also developing VTX002, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 inflammasome inhibitor to treat patients with cryopyrin-associated periodic syndrome. In addition, the company develops VTX3232, a CNS-penetrant NLRP3 inhibitor. Ventyx Biosciences, Inc. was incorporated in 2018 and is based in San Diego, California.